• 达成合作包裹北美洲、欧式、东南亚及马来西亚，已成定局促使HLX13在癌肿免疫力共同医疗区域的亚洲可及性

依照合同合同条款，复宏汉霖将担负HLX13的新产品的研发、生产的各种餐饮业化制造，并从成交中得到3.05亿元的风险收录，当中3一百万元为成交购车首汇款。当作中国仿制药与海洋生物技术体差不多药层面的引领者，山德士依然以“让健康保健生活化”为重任，依靠自己约1,300款产品的积累受益中国9亿我们。我院复宏汉霖携起手来山德士，将更加充分借力打力其成熟完善的中国网站与海洋生物技术体差不多药餐饮业化优势可言，变快HLX13在中国发展趋势海洋生物技术体药的市场的可及性。

复宏汉霖连接董事会、首席总裁连接官

朱俊博后表明

复宏汉霖首席首席总裁商务旅行成长官兼高等级总监裁

曹平的美女表示法

HLX13是复宏汉霖自研生物技术类似于药输水管线的极为重要组合，其原研药伊匹木单抗（Yervoy^®）当作亚洲地区最大首位CTLA-4阻止剂，已在多条的国家和中北部将建，适宜症包含携手并进纳武利尤单抗适用灰色素沉淀瘤、肝组织细胞癌等一系类适宜症。复宏汉霖已创造出一个一体化亚洲地区最大企业产品研发、药政集团注册及临床研究规划设计操作网络平台，并创立了合乎亚洲地区最大药品监督工作管理条件的研发和优质量管理工作管理质量管理管理体系，实现目标着力促进4款企业产品在淘宝销售市场将建纳斯达克上市。集团将详细促进HLX13的亚洲地区最大规划设计阶段，锐意创新于携手并进合作共赢伙伴们为亚洲地区最大爱美者供应太多高优质量管理可负担过重的的治疗设计方案。

 Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

• Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations

• Henlius to receive $31 million upfront, and up to $270 million in milestones

On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive commercialization rights for its self-developed ipilimumab biosimilar HLX13 in the United States, 42 European countries and regions, Japan, Canada, and Australia.

Under the agreement, Henlius will be responsible for development, manufacturing and commercial supply of HLX13, and is eligible to receive up to a total of $301 million, including a $31 million upfront and additional milestone payments. As the global leader in generic and biosimilar medicines, Sandoz is committed to its purpose of “pioneering access for patients” and has benefited over 900 million patients worldwide with approximately 1,300 products. This collaboration will leverage Sandoz’s established global network and commercialization expertise to accelerate the accessibility of HLX13 in mainstream biopharma markets.

“At Henlius, we remain deeply committed to delivering high-quality biologics to patients around the world,” said Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius. “Our collaboration with Sandoz marks another important step toward enhancing the global accessibility of our therapies. We believe that putting patients at the core of our globalization strategy is key to fulfilling our vision of ‘Developed in China, Access for the World.’”

“We’re excited to join forces with Sandoz,” said Ping Cao, Chief Business Officer and Senior Vice President of Henlius. “By combining Henlius’ proven strengths in biologics R&D and manufacturing with extensive global reach and commercialization expertise of Sandoz, we aim to accelerate the worldwide expansion of HLX13 and bring advanced treatment options to more patients across key markets.”

HLX13 is a key component of Henlius’ self-developed biosimilar pipeline. Its reference product, Yervoy^®, the world’s first CTLA-4 inhibitor, has been approved in various countries and regions in combination with nivolumab for the treatment of melanoma and hepatocellular carcinoma, among other indications. Henlius has established an integrated global platform for R&D, regulatory registration, and clinical operations, backed by a manufacturing and quality management system that meets global regulatory standards. The company has successfully launched four products in markets beyond China. Henlius is committed to advancing the global development of HLX13 and working with partners to provide more high-quality, affordable treatment options for patients worldwide.

*Yervoy^® is a registered trademark of Bristol-Myers Squibb (US)